INDV
NASDAQ
US
Indivior Pharmaceuticals, Inc. - Common Stock
$30,47
▼ $-0,18
(-0,59%)
Vol. 2.1M
10
Punteggio di Qualità
ok
Analisi approfondita
2/5
ok
Ricavi ✓
Utile netto ✓
>IPO ✗
Cap. mercato
$4.5B
P/E
35,8
ROE
159,1%
Margine
10,6%
D/E
2790,00
Beta
4,47
52W
$8–$38
Consenso Wall Street
13 analisti · Apr 20264
Acquisto forte
8
Compra
1
Mantieni
0
Vendi
0
Vendita forte
92,3%
Rating Compra
Grafico dei Prezzi
Titoli simili
TERN
Terns Pharmaceuticals Inc
$4.3B
CORT
Corcept Therapeutics Inc
P/E 34,5
$3.7B
LGND
Ligand Pharmaceuticals Inc
P/E 76,6
$3.7B
AMRX
Amneal Pharmaceuticals Inc
P/E 671,4
$4.0B
CRNX
Crinetics Pharmaceuticals Inc
$4.4B
GPCR
Structure Therapeutics Inc
$4.2B
EWTX
Edgewise Therapeutics Inc
$2.6B
LQDA
Liquidia Corp
$3.0B
TARS
Tarsus Pharmaceuticals Inc
$3.5B
SUPN
Supernus Pharmaceuticals Inc
$2.8B
Utili
Tasso di battuta: 100,0%| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Dic 2025 | $0,69 | $0,82 | +$0,13 |
| Set 2025 | $0,42 | $0,72 | +$0,30 |
| Giu 2025 | $0,27 | $0,51 | +$0,24 |
| Mar 2025 | $0,24 | $0,41 | +$0,17 |
Ricavi e utili trimestrali
| Trimestre | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Ricavi | — | $299.0M | $266.0M | $302.0M | $314.0M | $358.0M |
| Utile netto | — | $59.0M | $47.0M | $18.0M | $42.0M | $102.0M |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | 135.4% | 135.4% | 135.4% | 159.1% | 159.1% |
| P/E (TTM) | 12.88 | — | — | — | 33.96 | 35.84 |
| Net Margin | 6.0% | -4.4% | -4.4% | -4.4% | 10.6% | 10.6% |
| Gross Margin | 82.8% | 147.9% | 147.9% | 147.9% | 85.5% | 85.5% |
| D/E Ratio | — | 2790.00 | 2790.00 | 2790.00 | 2790.00 | 2790.00 |
| Current Ratio | 0.90 | 0.88 | 0.88 | 0.88 | 0.96 | 0.96 |
Rapporti chiave
ROA (TTM)
9,0%
P/S (TTM)
3,80
P/B
49,6
EPS (TTM)
$0,98
Crescita ricavi 3A
+14,5%
52W High
$38,00
52W Low
$7,62
$7,62
Intervallo 52 settimane
$38,00
Salute finanziaria
Flusso di cassa libero
-$245.0M
Debito netto
$156.0M
Liquidità
$195.0M
Debito totale
$351.0M
Aggiornato al Dic 31, 2025
Як INDV виглядає на тлі конкурентів у Pharmaceuticals?
Група порівняння: Mid-cap Pharmaceuticals ($2B+) · 25 компаній
Оцінка INDV vs аналоги Pharmaceuticals
P/E
35,8
▲
17%
sopra
peer
(30,7)
vs Peer
vs Settore
Sottovalutato
P/S
3,8
▼
44%
sotto
peer
(6,7)
vs Peer
vs Settore
Sottovalutato
P/B
49,6
▲
850%
sopra
peer
(5,2)
vs Peer
vs Settore
Sopravvalutato
Дивідендна дохідність
—
▼
0%
sotto
peer
(3,1%)
vs Peer
vs Settore
Rendimento basso
Прибутковість INDV vs аналоги Pharmaceuticals
ROE
159,1%
▲
710%
sopra
peer
(-26,1%)
vs Peer
vs Settore
Top livello
Net margin
10,6%
▲
830%
sopra
peer
(-1,5%)
vs Peer
vs Settore
Sotto media
Валова маржа
85,5%
▼
4%
sotto
peer
(88,9%)
vs Peer
vs Settore
Debole
ROA
9,0%
▲
195%
sopra
peer
(-9,5%)
vs Peer
vs Settore
Top livello
Фінансове здоровʼя INDV vs аналоги Pharmaceuticals
D/E ratio
2790,0
▲
10101%
sopra
peer
(27,4)
vs Peer
vs Settore
Debito alto
Поточна ліквідність
1,0
▼
73%
sotto
peer
(3,5)
vs Peer
vs Settore
Liquidità bassa
Beta
4,5
▲
658%
sopra
peer
(0,6)
vs Peer
vs Settore
Più volatile
Радар фундаменталів INDV
INDV
Mediana peer
Industria
INDV прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
INDV vs аналоги: ключові метрики
Segnali Correlati
Ultime notizie
Nessuna notizia correlata ancora